Related Experiment Video
Updated: May 16, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
1IsraGene, Haifa, Israel ; Cabernet Pharmaceuticals, R. David Thomas Center, One Science Drive, BOX 90344, Durham, NC 27708 USA.
The EPMA Journal
|December 4, 2012
Summary
Pharmacogenetics can personalize multiple sclerosis (MS) treatments by matching patients with the most effective and safe therapies, improving outcomes and preventing irreversible disability. This approach aids in predicting and preventing MS progression.
Area of Science:
- Neuroimmunology
- Pharmacogenetics
- Clinical Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune CNS disease impacting myelin.
- Current MS therapies benefit only subsets of patients.
- Early intervention is crucial to prevent irreversible disability.
Purpose of the Study:
- Review pharmacogenetic research for MS treatments.
- Assess pharmacogenetics' impact on MS drug efficacy and safety.
- Discuss biomarkers for personalized MS medication.
Main Methods:
- Literature review of pharmacogenetic studies in MS.
- Analysis of marketed and investigational MS therapies.
- Exploration of biomarker relevance for MS treatment.
Main Results:
- Pharmacogenetics offers potential for tailored MS treatment selection.
- Current research highlights variability in patient response to MS drugs.
- Biomarkers are key to predicting treatment success and safety.
Conclusions:
- Pharmacogenetics is vital for personalized MS treatment strategies.
- Biomarkers can guide prediction, prevention, and personalization of MS medications.
- Future research should focus on integrating pharmacogenetics into clinical practice.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...